US Stock Market Move | BEIGENE (ONC.US) gains 6%, institutions believe that the trend of innovative drugs is expected to continue.

On Friday, BEIGENE (ONC.US) rose by 6%, closing at $338.19. Huabao Fund emphasized that innovative drugs are still the strongest theme and are expected to continue. Starting in September, key clinical data for Chinese innovative drugs will be released at major conferences in the second half of the year such as the World Lung Cancer Congress, the European Oncology Congress, and the American Hematology Annual Meeting. This, combined with the arrival of the peak season for overseas MNCs to authorize and collaborate with Chinese potential BICs (several of which are already in late-stage negotiations), is expected to bring about a market feast for innovative drugs similar to the "China Innovative Drug Data Shining Stars" at the American Oncology Congress in May. Some analysts believe that from a performance perspective, the innovative drug sector is expected to continue to maintain a trend of high revenue growth and year-on-year reduction in losses. Some leading innovative drug companies have already reached the turning point of breaking even, and the industry as a whole is showing a positive trend towards profitability. In terms of innovative drugs going global, China's domestic innovative drugs have demonstrated international leading innovative capabilities, with active outbound licensing transactions in recent years reaching record highs in terms of quantity and amount. Over the next two to three years, many blockbuster drug patents from multinational pharmaceutical companies will expire, creating a massive gap that urgently needs to be filled. Multinational pharmaceutical companies are increasingly focusing on Chinese pipelines, frequently collaborating with Chinese pharmaceutical companies, and are expected to drive market expectations for the valuation of the innovative drug sector.